drugset / Trial / NCT00882414

Ferinject® in Patient With Thrombocytosis Secondary to Inflammatory Bowel Disease (IBD)

NCT00882414

Phase 2 Terminated 26 enrolled Vifor Pharma
RandomizedParallel-groupSingle-blindTreatment

Summary

The aim of this study is to show the benefits for patients, with a high platelet count, iron deficiency and IBD, receiving intravenous iron therapy.

Timeline

Start
2006-12
Primary completion
2010-01
Completion
2010-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Ferric carboxymaltose Other / unclassified 500 mg Intravenous
Subject Ferric carboxymaltose Other / unclassified 1000 mg Intravenous
Subject Ferric carboxymaltose Other / unclassified 1500 mg Intravenous